(S)-2-(2-Chloro-benzoylamino)-3-(4-propylcarbamoyloxy-phenyl)-propionic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-(2-Chloro-benzoylamino)-3-(4-propylcarbamoyloxy-phenyl)-propionic acid
• 英文别名: (2S)-2-[(2-chlorobenzoyl)amino]-3-[4-(propylcarbamoyloxy)phenyl]propanoic acid
• 化学式: C₂₀H₂₁ClN₂O₅
• 分子量: 404.85
• InChiKey: QVUGBFYAEPCUEO-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  正丙胺 、 Fmoc-L-酪氨酸 、 对硝基苯基氯甲酸酯 、 2-氯苯甲酸 生成 (S)-2-(2-Chloro-benzoylamino)-3-(4-propylcarbamoyloxy-phenyl)-propionic acid
  参考文献：
  名称：

  Solid-phase synthesis of dual α4β1/α4β7 integrin antagonists: two scaffolds with overlapping pharmacophores

  摘要：

  Two structural classes of dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists were investigated via solid-phase parallel synthesis. Using an acylated amino acid backbone, lead compounds containing biphenylalanine or tyrosine carbamate scaffolds were optimized for inhibition of alpha(4)beta(1)/VCAM and alpha(4)beta(7)/MAdCAM. A comparison of the structure-activity relationships in the inhibition of the alpha(4)beta(7)/MAdCAM interaction for substituted amines employed in both scaffolds suggests a similar binding mode for the compounds. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00597-8

文献信息

• Method for Augmenting B Cell Depletion
  申请人：Chan C. Andrew

  公开号：US20080075719A1

  公开（公告）日：2008-03-27

  The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. One method of promoting intravascular access is by the use of integrin antagonists. Methods of treating B cell disorders by this approach is also provided.
• TYROSINE DERIVATIVE
  申请人：Jackson David Y.

  公开号：US20090325962A1

  公开（公告）日：2009-12-31

  The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
• US7595399B2
  申请人：——

  公开号：US7595399B2

  公开（公告）日：2009-09-29
• [EN] METHOD FOR AUGMENTING B CELL DEPLETION<br/>[FR] METHODE PERMETTANT D'AUGMENTER L'APPAUVRISSEMENT DES LYMPHOCYTES B
  申请人：GENENTECH INC

  公开号：WO2005113003A2

  公开（公告）日：2005-12-01

  The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. One method of promoting intravascular access is by the use of integrin antagonists. Methods of treating B cell disorders by this approach is also provided.